Skip to main content
OpenTrials
Completed

NCT Number: NCT00896948

Study of Proteins in Head and Neck Cancer Cells

RATIONALE: Studying proteins in head and neck cancer cells in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.

PURPOSE: This laboratory study is looking at proteins in head and neck cancer cells.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 120 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Loading trial locations.

About this study

OBJECTIVES:

  • Define the function and mechanism of LZAP in regulating ARF.
  • Determine the mechanism and biological consequences of LZAP inhibition of NF-κB.
  • Determine if LZAP has tumor suppressor activity by conditional targeting of LZAP in mice.

OUTLINE: Using molecular laboratory techniques, this study examines the biochemical mechanisms by which LZAP activates transcriptional, tumor suppressive activity (both p53-dependent and p53-independent) of ARF and inhibits transcriptional, tumorigenic activity of NF-kB. LZAP regulation of newly identified ARF activities, such as S-phase delay and ARF-mediated B23 degradation are also evaluated. LZAP's tumor suppressive activity is assessed in vivo using a conditional knockout vector to target LZAP in mice and to observe for spontaneous and induced tumor formation. Laboratory analyses used to determine study endpoints include standard recombinant DNA, recombinant protein expression and purification, cell culture and transfection, cell labeling, reporter assays, flow cytometry, yeast-two hybrid, immunoprecipitation, immunoblotting, immunofluorescence, TUNEL assay, ELISA assay, Southern blotting, and protein and gene expression.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

DISEASE CHARACTERISTICS:

  • Head and neck cancer tumor cell line

PATIENT CHARACTERISTICS:

  • Not specified

PRIOR CONCURRENT THERAPY:

  • Not specified

Treatment and study plan

Southern blotting

Genetic

TdT-mediated dUTP nick end labeling assay

Genetic

gene expression analysis

Genetic

protein expression analysis

Genetic

flow cytometry

Other

fluorescent antibody technique

Other

immunoenzyme technique

Other

immunohistochemistry staining method

Other

immunologic technique

Other

Primary outcomes

  1. Function and mechanism of LZAP in regulating ARF

  2. Mechanism and biological consequences of LZAP inhibition of NF-κB

  3. Determination of LZAP tumor suppressor activity

Sponsors and collaborators

Lead sponsor

Vanderbilt University Medical Center

Other

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Novel Protein Regulator of Tumor Suppressor ARF & NF-κB

Important dates

Study start
2005
First posted
May 12, 2009
Registry last updated
Mar 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.